Search Results - "ANGULO, Ana"

Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer by Miller, Todd W, Hennessy, Bryan T, González-Angulo, Ana M, Fox, Emily M, Mills, Gordon B, Chen, Heidi, Higham, Catherine, García-Echeverría, Carlos, Shyr, Yu, Arteaga, Carlos L

“…Many breast cancers exhibit a degree of dependence on estrogen for tumor growth. Although several therapies have been developed to treat individuals with…”
Get full text

Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance by Balko, Justin M, Cook, Rebecca S, Vaught, David B, Kuba, María G, Miller, Todd W, Bhola, Neil E, Sanders, Melinda E, Granja-Ingram, Nara M, Smith, J Joshua, Meszoely, Ingrid M, Salter, Janine, Dowsett, Mitch, Stemke-Hale, Katherine, González-Angulo, Ana M, Mills, Gordon B, Pinto, Joseph A, Gómez, Henry L, Arteaga, Carlos L

“…By digital profiling of residual breast tumors after neoadjuvant therapy, the authors identify gene expression patterns that correspond with a higher risk of…”
Get full text

Targeting the Hepatocyte Growth Factor–cMET Axis in Cancer Therapy by BLUMENSCHEIN, George R, MILLS, Gordon B, GONZALEZ-ANGULO, Ana M

“…The hepatocyte growth factor (HGF) and its receptor, the transmembrane tyrosine kinase cMET, promote cell proliferation, survival, motility, and invasion as…”
Get full text

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline by Harris, Lyndsay N, Ismaila, Nofisat, McShane, Lisa M, Andre, Fabrice, Collyar, Deborah E, Gonzalez-Angulo, Ana M, Hammond, Elizabeth H, Kuderer, Nicole M, Liu, Minetta C, Mennel, Robert G, Van Poznak, Catherine, Bast, Robert C, Hayes, Daniel F

“…To provide recommendations on appropriate use of breast tumor biomarker assay results to guide decisions on adjuvant systemic therapy for women with…”
Get full text

Metformin: A Therapeutic Opportunity in Breast Cancer by GONZALEZ-ANGULO, Ana M, MERIC-BERNSTAM, Funda

“…Two important, related pathways are involved in cancer growth: the insulin/insulin-like growth factor-1 (IGF1) signaling pathway, which is activated when…”
Get full text

Targeting the Phosphatidylinositol 3‐Kinase Signaling Pathway in Breast Cancer by Hernandez‐Aya, Leonel F., Gonzalez‐Angulo, Ana M.

“…Learning Objectives After completing this course, the reader will be able to: Describe how PTEN loss, PIK3CA mutations, and AKT dysregulation affect the…”
Get full text

Lactate Dehydrogenase B: A Metabolic Marker of Response to Neoadjuvant Chemotherapy in Breast Cancer by DENNISON, Jennifer B, MOLINA, Jennifer R, BROWN, Robert E, MILLS, Gordon B, MITRA, Shreya, GONZALEZ-ANGULO, Ana M, BALKO, Justin M, KUBA, María G, SANDERS, Melinda E, PINTO, Joseph A, GOMEZ, Henry L, ARTEAGA, Carlos L

“…Although breast cancers are known to be molecularly heterogeneous, their metabolic phenotype is less well-understood and may predict response to chemotherapy…”
Get full text

Rax regulates hypothalamic tanycyte differentiation and barrier function in mice by Miranda-Angulo, Ana L., Byerly, Mardi S., Mesa, Janny, Wang, Hong, Blackshaw, Seth

“…ABSTRACT The wall of the ventral third ventricle is composed of two distinct cell populations: tanycytes and ependymal cells. Tanycytes regulate many aspects…”
Get full text

Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline by Van Poznak, Catherine, Somerfield, Mark R, Bast, Robert C, Cristofanilli, Massimo, Goetz, Matthew P, Gonzalez-Angulo, Ana M, Hicks, David G, Hill, Elizabeth G, Liu, Minetta C, Lucas, Wanda, Mayer, Ingrid A, Mennel, Robert G, Symmans, William F, Hayes, Daniel F, Harris, Lyndsay N

“…To provide recommendations on the appropriate use of breast tumor biomarker assay results to guide decisions on systemic therapy for metastatic breast cancer…”
Get full text

Loss of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Metastatic Sites of HER2-Overexpressing Primary Breast Tumors by Niikura, Naoki, Liu, Jun, Hayashi, Naoki, Mittendorf, Elizabeth A, Gong, Yun, Palla, Shana L, Tokuda, Yutaka, Gonzalez-Angulo, Ana M, Hortobagyi, Gabriel N, Ueno, Naoto T

“…We evaluated whether patients with human epidermal growth factor receptor 2 (HER2) -positive primary breast tumors had metastatic tumors that were HER2…”
Get full text

Beta-Blocker Use Is Associated With Improved Relapse-Free Survival in Patients With Triple-Negative Breast Cancer by Melhem-Bertrandt, Amal, Chavez-Macgregor, Mariana, Lei, Xiudong, Brown, Erika N, Lee, Richard T, Meric-Bernstam, Funda, Sood, Anil K, Conzen, Suzanne D, Hortobagyi, Gabriel N, Gonzalez-Angulo, Ana-Maria

“…To examine the association between beta-blocker (BB) intake, pathologic complete response (pCR) rates, and survival outcomes in patients with breast cancer…”
Get full text

Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer by LIEDTKE, Cornelia, MAZOUNI, Chafika, CRISTOFANILLI, Massimo, HORTOBAGYI, Gabriel N, PUSZTAI, Lajos, HESS, Kenneth R, ANDRE, Fabrice, TORDAI, Attila, MEJIA, Jaime A, SYMMANS, W. Fraser, GONZALEZ-ANGULO, Ana M, HENNESSY, Bryan, GREEN, Marjorie

“…Triple-negative breast cancer (TNBC) is defined by the lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2…”
Get full text

PD-L1 expression in triple-negative breast cancer by Mittendorf, Elizabeth A, Philips, Anne V, Meric-Bernstam, Funda, Qiao, Na, Wu, Yun, Harrington, Susan, Su, Xiaoping, Wang, Ying, Gonzalez-Angulo, Ana M, Akcakanat, Argun, Chawla, Akhil, Curran, Michael, Hwu, Patrick, Sharma, Padmanee, Litton, Jennifer K, Molldrem, Jeffrey J, Alatrash, Gheath

“…Early-phase trials targeting the T-cell inhibitory molecule programmed cell death ligand 1 (PD-L1) have shown clinical efficacy in cancer. This study was…”
Get more information

Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast Cancer by JIRALERSPONG, Sao, PALLA, Shana L, GIORDANO, Sharon H, MERIC-BERNSTAM, Funda, LIEDTKE, Cornelia, BARNETT, Chad M, HSU, Limin, HUNG, Mien-Chie, HORTOBAGYI, Gabriel N, GONZALEZ-ANGULO, Ana M

“…Population studies have suggested that metformin use in diabetic patients decreases cancer incidence and mortality. Metformin inhibits the growth of cancer…”
Get full text

Effect of metformin on survival outcomes in diabetic patients with triple receptor‐negative breast cancer by Bayraktar, Soley, Hernadez‐Aya, Leonel F., Lei, Xiudong, Meric‐Bernstam, Funda, Litton, Jennifer K., Hsu, Limin, Hortobagyi, Gabriel N., Gonzalez‐Angulo, Ana M.

“…BACKGROUND: Recent observational studies have shown that metformin use in diabetic patients decreases both cancer incidence and mortality. Metformin use is…”
Get full text

Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline by GIORDANO, Sharon H, TEMIN, Sarah, LIN, Nancy U, MODI, Shanu, PATT, Debra A, PEREZ, Edith A, PERLMUTTER, Jane, RAMAKRISHNA, Naren, WINER, Eric P, KIRSHNER, Jeffrey J, CHANDARLAPATY, Sarat, CREWS, Jennie R, DAVIDSON, Nancy E, ESTEVA, Francisco J, GONZALEZ-ANGULO, Ana M, KROP, Ian, LEVINSON, Jennifer

“…To provide evidence-based recommendations to practicing oncologists and others on systemic therapy for patients with human epidermal growth factor receptor 2…”
Get full text

Sympathovagal quotient and resting-state functional connectivity of control networks are related to gut Ruminococcaceae abundance in healthy men by Miranda-Angulo, Ana L., Sánchez-López, Juan D., Vargas-Tejada, Daniel A., Hawkins-Caicedo, Valentina, Calderón, Juan C., Gallo-Villegas, Jaime, Alzate-Restrepo, Juan F., Suarez-Revelo, Jazmin X., Castrillón, Gabriel

“…Heart rate variability (HRV), brain resting-state functional connectivity (rsFC), and gut microbiota (GM) are three recognized indicators of health…”
Get full text

Future of Personalized Medicine in Oncology: A Systems Biology Approach by GONZALEZ-ANGULO, Ana Maria, HENNESSY, Bryan T. J, MILLS, Gordon B

“…The development of cost-effective technologies able to comprehensively assess DNA, RNA, protein, and metabolites in patient tumors has fueled efforts to tailor…”
Get full text

High ERK Protein Expression Levels Correlate with Shorter Survival in Triple‐Negative Breast Cancer Patients by Bartholomeusz, Chandra, Gonzalez‐Angulo, Ana M., Liu, Ping, Hayashi, Naoki, Lluch, Ana, Ferrer‐Lozano, Jaime, Hortobágyi, Gabriel N.

“…The mitogen‐activated protein kinase (MAPK) signaling pathway is known to be activated in triple‐negative breast cancer (TNBC). Extracellular signal–related…”
Get full text

Clinical Impact of Delaying Initiation of Adjuvant Chemotherapy in Patients With Breast Cancer by DE MELO GAGLIATO, Debora, GONZALEZ-ANGULO, Ana M, XIUDONG LEI, THERIAULT, Richard L, GIORDANO, Sharon H, VALERO, Vicente, HORTOBAGYI, Gabriel N, CHAVEZ-MACGREGOR, Mariana

“…For patients with breast cancer (BC), the optimal time to initiation of adjuvant chemotherapy (TTC) after definitive surgery is unknown. We evaluated the…”
Get full text